ADVENTRX Pharmaceuticals, Inc. – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 6 PAGES: 90

The report provides data on the ADVENTRX Pharmaceuticals’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ADVENTRX Pharmaceuticals’s corporate website, SEC filings, investor presentations and featured press releases, both from ADVENTRX Pharmaceuticals and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									   ADVENTRX Pharmaceuticals, Inc. – Product Pipeline
                 Review – 2012


                                                                                          Reference Code: GMDHC02142CDB
                                                                                                 Publication Date: MAY 2012




ADVENTRX Pharmaceuticals, Inc. – Product Pipeline Review – 2012                           GMDHC02142CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
ADVENTRX Pharmaceuticals, Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 6
ADVENTRX Pharmaceuticals, Inc. Snapshot..................................................................................................................................... 7
    ADVENTRX Pharmaceuticals, Inc. Overview ................................................................................................................................ 7
    Key Information ............................................................................................................................................................................. 7
    Key Facts....................................................................................................................................................................................... 7
ADVENTRX Pharmaceuticals, Inc. – Research and Development Overview..................................................................................... 8
    Key Therapeutic Areas .................................................................................................................................................................. 8
ADVENTRX Pharmaceuticals, Inc. – Pipeline Review ..................................................................................................................... 10
    Pipeline Products by Stage of Development ............................................................................................................................... 10
    Pipeline Products – Monotherapy ............................................................................................................................................... 11
ADVENTRX Pharmaceuticals, Inc. – Pipeline Products Glance....................................................................................................... 12
    ADVENTRX Pharmaceuticals, Inc. – Late Stage Pipeline ........................................................................................................... 12
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 12
    ADVENTRX Pharmaceuticals, Inc. Clinical Stage Pipeline Products .......................................................................................... 13
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 13
    ADVENTRX Pharmaceuticals, Inc. – Early Stage Pipeline Products........................................................................................... 14
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 14
ADVENTRX Pharmaceuticals, Inc. – Drug Profiles .......................................................................................................................... 15
    ANX-015 ...................................................................................................................................................................................... 15
        Product Description................................................................................................................................................................. 15
        Mechanism of Action ............................................................................................................................................................... 15
        R&D Progress ......................................................................................................................................................................... 15
    ANX-016 ...................................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    ANX-188 ...................................................................................................................................................................................... 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 17
    ANX-201 ...................................................................................................................................................................................... 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress ......................................................................................................................................................................... 18
    ANX-513 ...................................................................................................................................................................................... 19
        Product Description................................................................................................................................................................. 19
        Mechanism of Action ............................................................................................................................................................... 19
        R&D Progress ......................................................................................................................................................................... 19
    ANX-514 ...................................................................................................................................................................................... 20
        Product Description................................................................................................................................................................. 20



ADVENTRX Pharmaceuticals, Inc. – Product Pipeline Review – 2012                                                                        GMDHC02142CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
ADVENTRX Pharmaceuticals, Inc. – Product Pipeline Review




        Mechanism of Action ............................................................................................................................................................... 20
        R&D Progress ......................................................................................................................................................................... 20
ADVENTRX Pharmaceuticals, Inc. – Pipeline Analysis .................................................................................................................... 22
    ADVENTRX Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class ........................................................................... 22
    ADVENTRX Pharmaceuticals, Inc. – Pipeline Products By Target.............................................................................................. 24
    ADVENTRX Pharmaceuticals, Inc. – Pipeline Products by Route of Administration ................................................................... 25
    ADVENTRX Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action....................................................................... 26
ADVENTRX Pharmaceuticals, Inc. – Recent Pipeline Updates ...................................................................................................... 27
ADVENTRX Pharmaceuticals, Inc. - Dormant Projects .................................................................................................................... 29
ADVENTRX Pharmaceuticals, Inc. - Discontinued Pipeline Products .............................................................................................. 30
    Discontinued Pipeline Product Profiles ........................................................................................................................................ 30
        5-Fluorouracil + Avastin + ANX-510 ........................................................................................................................................ 30
        ANX-570 ................................................................................................................................................................................. 30
        ANX-575 ................................................................................................................................................................................. 31
        BlockAide/CR .......................................................................................................................................................................... 31
        BlockAide/VP .......................................................................................................................................................................... 31
        CoFactor + 5-Fluorouracil ....................................................................................................................................................... 31
        EradicAide............................................................................................................................................................................... 32
        Exelbine .................................................................................................................................................................................. 32
ADVENTRX Pharmaceuticals, Inc. – Company Statement .............................................................................................................. 33
ADVENTRX Pharmaceuticals, Inc. – Locations And Subsidiaries.................................................................................................... 36
    Head Office.................................................................................................................................................................................. 36
    Other Locations & Subsidiaries ................................................................................................................................................... 36
ADVENTRX Pharmaceuticals, Inc., Recent Developments.............................................................................................................. 37
    ADVENTRX Pharmaceuticals, Inc.- Press Release .................................................................................................................... 37
        Dec 01, 2009: ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data For ANX-514 .......................................... 37
        Aug 04, 2009: ADVENTRX Narrows Prior Guidance On NDA Submission Timeline .............................................................. 37
        May 07, 2009: ADVENTRX Announces Results From ANX-514 Bioequivalence Study ......................................................... 38
        Feb 05, 2009: ADVENTRX Completes Patient Enrollment In ANX-514 Bioequivalence Study .............................................. 39
Financial Deals Landscape .............................................................................................................................................................. 40
    ADVENTRX Pharmaceuticals, Inc., Deals Summary .................................................................................................................. 40
ADVENTRX Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details ........................................................................... 42
    Asset Transactions ...................................................................................................................................................................... 42
        ADVENTRX Pharma To Acquire Pharma Products ................................................................................................................ 42
    Licensing Agreements ................................................................................................................................................................. 44
        ADVENTRX Pharma Enters Into Licensing Agreement With Theragence .............................................................................. 44
        SD Pharma Enters Into Licensing Agreement With Shin Poong ............................................................................................. 46
        SD Pharma Enters Into Licensing Agreement With Theragenex ............................................................................................ 48
        Adventrx Pharma Enters Into Licensing Agreement With Theragenex ................................................................................... 50
        ADVENTRX Enters Into License Agreement With SD Pharma ............................................................................................... 52
    Equity Offering ............................................................................................................................................................................. 53
        ADVENTRX Files Registration Statement For Public Offering Of Securities For $150 Million ................................................ 53
        ADVENTRX Pharma Completes Underwritten Public Offering Of Common Stock For $17 Million......................................... 55
        ADVENTRX Pharma Completes Registered Direct Offering Of Its Units For $22.5 Million .................................................... 57


ADVENTRX Pharmaceuticals, Inc. – Product Pipeline Review – 2012                                                                        GMDHC02142CDB / Published MAY 2012
©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                      Page(3)
ADVENTRX Pharmaceuticals, Inc. – Product Pipeline Review




         ADVENTRX Completes Private Placement Of Series F Convertible Preferred Stock For $19 Million .................................... 59
         ADVENTRX Pharma Completes Placement Of Series E Preferred Stock For $19 Million ..................................................... 61
         ADVENTRX Completes Private Placement Of Series D Convertible Preferred Stock For $11 Million.................................... 63
         ADVENTRX Pharma Completes Private Placement Of $0.92 Million ..................................................................................... 65
         ADVENTRX Pharma Completes Public Offering Of $1.36 Million........................................................................................... 67
         ADVENTRX Pharma Completes Private Placement Of $2 Million .......................................................................................... 69
         ADVENTRX Completes Private Placement Of $8 Million ........................................................................
								
To top